[1] |
中华医学会呼吸病学分会肺栓塞与肺血管病学组, 中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会, 全国肺栓塞与肺血管病防治协作组, 等. 中国肺动脉高压诊断与治疗指南(2021版)[J]. 中华医学杂志, 2021, 101(1): 11-51.
|
[2] |
Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension [J]. Lancet Respir Med, 2016, 4(4): 306-322.
|
[3] |
Sun W, Chan SY. Pulmonary arterial stiffness: an early and pervasive driver of pulmonary arterial hypertension [J]. Front Med(Lausanne), 2018, 204(5): 1-8.
|
[4] |
Deshwal H, Weinstein T, Sulica R. Advances in the management of pulmonary arterial hypertension [J]. Investig Med, 2021, 69(7): 1270-1280.
|
[5] |
Kudryashova TV, Goncharov DA, Pena A, et al. Hippo-integrin-linked kinase cross-talk controls self-sustaining proliferation and survival in pulmonary hypertension [J]. Am J Respir Crit Care Med, 2016, 194(7): 866-877.
|
[6] |
Wang Q, Shi W, Zhang Q, et al. Inhibition of Siah2 ubiquitin ligase ameliorates monocrotaline-induced pulmonary arterial remodeling through inactivation of YAP [J]. Life Sci, 2020, 242: 117159. doi: 10.1016/j.lfs.2019.117159.
|
[7] |
Xiang L, Li Y, Deng X, et al. Natural plant products in treatment of pulmonary arterial hypertension [J]. Pulm Circ, 2018, 8(3): 1-44.
|
[8] |
Jin H, Lian N, Zhang F, et al. Inhibition of YAP signaling contributes to senescence of hepatic stellate cells induced by tetramethylpyrazine [J]. Eur J Pharm Sci, 2017, 96: 323-333. doi: 10.1016/j.ejps.2016.10.002.
|
[9] |
杨永超, 杨东鹏, 杨博, 等. 野百合碱诱导的肺动脉高压大鼠心肺组织变化研究[J]. 中国呼吸与危重监护杂志, 2015, 14(4): 380-384. YANG Yongchao, YANG Dongpeng, YANG Bo, et al. Pathological changes of heart and lung tissues in rats with pulmonary hypertension induced by monocrotaline [J]. Chinese Journal of Respiratory and Critical Care Medicine, 2015, 14(4): 380-384.
|
[10] |
刘莹, 董文鹏, 陈长富, 等. Caspase-1抑制剂在野百合碱诱导的肺动脉高压大鼠中的作用[J]. 广东医学, 2017, 38(23): 3566-3570. LIU Ying, DONG Wenpeng, CHEN Changfu, et al. Effect of caspase-1 inhibitor on rats with pulmonary hypertension induced by monocrotaline [J]. Guangdong Medical Journal, 2017, 38(23): 3566-3570.
|
[11] |
刘莹, 董文鹏, 陈长富, 等. 粉防己碱对肺动脉高压大鼠中NLRP3炎性小体表达研究[J]. 临床心血管病杂志, 2017, 33(11): 1102-1106. LIU Ying, DONG Wenpeng, CHEN Changfu, et al. Impact of the NLRP3 inflammasome on tetrandrine in rats with pulmonary arterial hypertension [J]. Journal of Clinical Cardiology(China), 2017, 33(11): 1102-1106.
|
[12] |
Huang H, Kong L, Luan S, et al. Ligustrazine suppresses platelet-derived growth factor-BB-induced pulmonary artery smooth muscle cell proliferation and inflammation by regulating the PI3K/AKT signaling pathway [J]. Am J Chin Med, 2021, 49(2): 437-459.
|
[13] |
Chen Y, Lu W, Yang K, et al. Tetramethylpyrazine: a promising drug for the treatment of pulmonary hypertension [J]. Br J Pharmacol, 2020, 177(12): 2743-2764.
|
[14] |
杨东鹏, 杨永超, 吕珊珊, 等. iNOS和PKG-1在白藜芦醇防治肺动脉高压中的作用[J]. 实用医学杂志, 2015, 31(10): 1577-1579. YANG Dongpeng, YANG Yongchao, LYU Shanshan, et al. Mechanism of resveratrol in prevention and treatment of pulmonary artery hypertension [J]. The Journal of Practical Medicine, 2015, 31(10): 1577-1579.
|
[15] |
Ge XY, Zhu TT, Yao MZ, et al. MicroRNA-137 inhibited hypoxia-induced proliferation of pulmonary artery smooth muscle cells by targeting calpain-2 [J]. Biomed Res Int, 2021, 2021: 2202888. doi: 10.1155/2021/2202888.
|
[16] |
吉新彦, 钟国轩, 赵斌. 哺乳动物Hippo信号通路分子机制研究进展[J]. 遗传, 2017, 39(7): 546-567. JI Xinyan, ZHONG Guoxuan, ZHAO Bin. Molecular mechanisms of the mammalian hippo signaling pathway [J]. Hereditas(Beijing), 2017, 39(7): 546-567.
|
[17] |
Yu Y, Su X, Qin Q, et al. Yes-associated protein and transcriptional coactivator with PDZ-binding motif as new targets in cardiovascular diseases [J]. Pharmacol Res, 2020, 159: 105009. doi: 10.1016/j.phrs.2020.105009.
|
[18] |
Acharya AP, Tang Y, Bertero T, et al. Simultaneous pharmacologic inhibition of yes-associated protein 1 and glutaminase 1 via inhaled poly(lactic-co-glycolic)acid-encapsulated microparticles improves pulmonary hypertension [J]. J Am Heart Assoc, 2021, 10(12): 1-15.
|
[19] |
Zuo W, Liu N, Zeng Y, et al. Luteolin ameliorates experimental pulmonary arterial hypertension via suppressing hippo-YAP/PI3K/AKT signaling pathway [J]. Front Pharmacol, 2021, 12: doi: 10.3389/fphar.2021.663551.
|
[20] |
Zhang Q, Li W, Zhu Y, et al. Activation of AMPK inhibits galectin-3-induced pulmonary artery smooth muscle cells proliferation by upregulating hippo signaling effector YAP [J]. Mol Cell Biochem, 2021, 476(8): 3037-3049.
|
[21] |
Mandras SA, Mehta HS, Vaidya A. Pulmonary hypertension: a brief guide for clinicians [J]. Mayo Clin Proc, 2020, 95(9): 1978-1988.
|
[22] |
Gaine S, Mclaughlin V. Pulmonary arterial hypertension: tailoring treatment to risk in the current era [J]. Eur Respir Rev, 2017, 26(146): 1-10.
|
[23] |
Yu L, Huang X, Huang K, et al. Ligustrazine attenuates the platelet-derived growth factor-BB-induced proliferation and migration of vascular smooth muscle cells by interrupting extracellular signal-regulated kinase and P38 mitogen-activated protein kinase pathways [J]. Mol Med Rep, 2015, 12(1): 705-711.
|
[24] |
Peng C, Zhang S, Liu H, et al. A newly synthesized ligustrazine stilbene derivative inhibits PDGF-BB induced vascular smooth muscle cell phenotypic switch and proliferation via delaying cell cycle progression [J]. Eur J Pharmacol, 2017, 814: 106-113. doi: 10.1016/j.ejphar.2017.08.008.
|
[25] |
杨敏, 李慧, 朱博文, 等. 川芎嗪抑制血管重塑的研究进展[J]. 中国中西医结合杂志, 2018, 38(3): 379-383.
|